https://egfrcancer.org/2023/12/24/novel-antibody-drug-conjugate-shows-efficacy-in-advanced-egfr-mutated-nsclc/
Novel ADC Shows Efficacy in Advanced EGFR+ NSCLC | EGFR Lung Cancer Resisters
Jan 11, 2024 - Treatment with patritumab deruxtecan (HER3-DXd) after progression with an EGFR TKI and platinum-based chemotherapy resulted in "clinically meaningful and...
lung cancernoveladcshowsefficacy
https://ascopost.com/news/april-2026/first-line-zongertinib-in-advanced-her2-mutant-nsclc/
First-Line Zongertinib in Advanced HER2-Mutant NSCLC - The ASCO Post
In a phase IA to IB trial reported in The New England Journal of Medicine, Heymach et al found that first-line zongertinib was active in patients with advanced...
first lineadvanced
https://pubmed.ncbi.nlm.nih.gov/35491960/
Efficacy of first-line immune checkpoint inhibitors in patients with advanced NSCLC with KRAS, MET,...
The benefit of the first-line ICI was similar in advanced NSCLC regardless of the driver alterations, except for MET alterations.